Antenatal magnesium sulfate to prevent cerebral palsy

Amy K. Keir; Emily Shepherd; Sarah McIntyre; Alice Rumbold; Charlotte Groves; Caroline Crowther; Emily Joy Callander

doi:10.1136/archdischild-2021-321817

Antenatal magnesium sulfate to prevent cerebral palsy

Amy K. Keir, Emily Shepherd, Sarah McIntyre, Alice Rumbold, Charlotte Groves, Caroline Crowther, Emily Joy Callander

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

Magnesium sulfate given to women before birth at <30 weeks' gestation reduces the risk of cerebral palsy in their children. Our study aimed to assess the impact of a local quality improvement programme, primarily using plan-do-study-act cycles, to increase the use of antenatal magnesium sulfate. After implementing our quality improvement programme, an average of 86% of babies delivered at <30 weeks' gestation were exposed to antenatal magnesium sulfate compared with a historical baseline rate of 63%. Our study strengthens the case for embedding quality improvement programmes in maternal perinatal care to reduce the impact of cerebral palsy on families and society.

Original language	English
Pages (from-to)	F225-F227
Journal	Archives of Disease in Childhood: Fetal and Neonatal Edition
Volume	107
Issue number	2
DOIs	https://doi.org/10.1136/archdischild-2021-321817
Publication status	Published or Issued - 1 Mar 2022

Keywords

health services research
neonatology

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Obstetrics and Gynaecology

Access to Document

10.1136/archdischild-2021-321817

Link to publication in Scopus

Cite this

@article{8525fccb127d49fa9c856f733a33c02f,

title = "Antenatal magnesium sulfate to prevent cerebral palsy",

abstract = "Magnesium sulfate given to women before birth at <30 weeks' gestation reduces the risk of cerebral palsy in their children. Our study aimed to assess the impact of a local quality improvement programme, primarily using plan-do-study-act cycles, to increase the use of antenatal magnesium sulfate. After implementing our quality improvement programme, an average of 86% of babies delivered at <30 weeks' gestation were exposed to antenatal magnesium sulfate compared with a historical baseline rate of 63%. Our study strengthens the case for embedding quality improvement programmes in maternal perinatal care to reduce the impact of cerebral palsy on families and society.",

keywords = "health services research, neonatology",

author = "Keir, {Amy K.} and Emily Shepherd and Sarah McIntyre and Alice Rumbold and Charlotte Groves and Caroline Crowther and Callander, {Emily Joy}",

note = "Funding Information: The Health Services Charitable Gifts Board (HSCGB) generously funds the salary of the nursing and midwifery co-leads for the QI programme. AKK and EJC are in receipt of National Health and Medical Research Council (NHMRC) Fellowships (APP1161379 and APP1159536, respectively).",

year = "2022",

month = mar,

day = "1",

doi = "10.1136/archdischild-2021-321817",

language = "English",

volume = "107",

pages = "F225--F227",

journal = "Archives of Disease in Childhood: Fetal and Neonatal Edition",

issn = "1359-2998",

publisher = "BMJ Publishing Group",

number = "2",

}

TY - JOUR

T1 - Antenatal magnesium sulfate to prevent cerebral palsy

AU - Keir, Amy K.

AU - Shepherd, Emily

AU - McIntyre, Sarah

AU - Rumbold, Alice

AU - Groves, Charlotte

AU - Crowther, Caroline

AU - Callander, Emily Joy

N1 - Funding Information: The Health Services Charitable Gifts Board (HSCGB) generously funds the salary of the nursing and midwifery co-leads for the QI programme. AKK and EJC are in receipt of National Health and Medical Research Council (NHMRC) Fellowships (APP1161379 and APP1159536, respectively).

PY - 2022/3/1

Y1 - 2022/3/1

N2 - Magnesium sulfate given to women before birth at <30 weeks' gestation reduces the risk of cerebral palsy in their children. Our study aimed to assess the impact of a local quality improvement programme, primarily using plan-do-study-act cycles, to increase the use of antenatal magnesium sulfate. After implementing our quality improvement programme, an average of 86% of babies delivered at <30 weeks' gestation were exposed to antenatal magnesium sulfate compared with a historical baseline rate of 63%. Our study strengthens the case for embedding quality improvement programmes in maternal perinatal care to reduce the impact of cerebral palsy on families and society.

AB - Magnesium sulfate given to women before birth at <30 weeks' gestation reduces the risk of cerebral palsy in their children. Our study aimed to assess the impact of a local quality improvement programme, primarily using plan-do-study-act cycles, to increase the use of antenatal magnesium sulfate. After implementing our quality improvement programme, an average of 86% of babies delivered at <30 weeks' gestation were exposed to antenatal magnesium sulfate compared with a historical baseline rate of 63%. Our study strengthens the case for embedding quality improvement programmes in maternal perinatal care to reduce the impact of cerebral palsy on families and society.

KW - health services research

KW - neonatology

UR - http://www.scopus.com/inward/record.url?scp=85109397600&partnerID=8YFLogxK

U2 - 10.1136/archdischild-2021-321817

DO - 10.1136/archdischild-2021-321817

M3 - Article

C2 - 34233908

AN - SCOPUS:85109397600

VL - 107

SP - F225-F227

JO - Archives of Disease in Childhood: Fetal and Neonatal Edition

JF - Archives of Disease in Childhood: Fetal and Neonatal Edition

SN - 1359-2998

IS - 2

ER -